Kyle Bass, the hedge fund manager vilified by the pharmaceutical industry and much of the patent bar, just gave his detractors more reason to resent him. The U.S. Patent and Trademark Office has agreed within the last week to institute trials for six of the drug patents Bass has challenged.
Earlier this month, the PTO’s Patent Trial and Appeal Board (PTAB) agreed to hear an additional pharma patent challenge filed by Bass through his Coalition for Affordable Drugs, bringing the total number of instituted challenges brought by the hedge fund manager to seven.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
